AngioDynamics, Inc. (ANGO) SEC Filings & Earnings Calls

Increased Net Loss

“Net loss increased by $2.7 million to $36.7 million” · word for word

Med Device Softness

“Our Med Device business increased 2.6% in fiscal year 2026, driven mainly by growth in the Core and Venous product lines which was partially offset by softness in Ports and other Oncology products.” · word for word

Tariff exposure and manufacturing transition may pressure margins in H2.

“Gross margin expected lower in H2; tariff-related expenses $0.9M; manufacturing transition ongoing.”

CEO transition introduces execution risk despite orderly succession.

“CEO retirement and appointment of new CEO effective Nov 2, 2026.”

Cash Burn

“Cash used in operating activities of $15.3 million and cash balance decreased to $34.0 million from $53.9 million.”

Macroeconomic Headwinds

“The current macroeconomic environment continues to impact our business and may continue to pose future risks.” · word for word

CEO transition may introduce execution risk during leadership change.

“Departure of long-time CEO Jim Clemmer; new CEO Eric Honroth effective Nov 2, 2026.”

CEO succession risk

“Mr. Clemmer has announced his intention to retire on the earlier of November 30, 2026 and appointment of a successor Chief Executive Officer.” · word for word

CEO succession risk

“Mr. Clemmer has announced his intention to retire on the earlier of November 30, 2026 and appointment of a successor Chief Executive Officer.” · word for word

Net Loss Widening

“Net loss increased by $2.7 million to $36.7 million” · word for word

Med Device Margin Decline

“Med Device gross margin % of sales 46.7% (down from 47.7%)”

Tariff Exposure

“Tariffs, which negatively impacted gross margin by $3.2 million;” · word for word

Restructuring Execution Risk

“The restructuring activities associated with the modified Plan are expected to be completed in the first quarter of fiscal year 2027.” · word for word

Tariff headwinds expected to persist in FY2027 with similar impact to FY2026.

“For fiscal 2027, the Company expects a tariff impact broadly similar to fiscal 2026, based on its current view of the tariff situation, which remains dynamic and subject to change.” · word for word

AngioVac faced tough comparison with 15.8% decline in Q4.

“AngioVac faced a tough comparison, declining 15.8% versus prior year.” · word for word

Litigation outcome uncertain; could result in costs or adverse judgment.

“Factors that may affect the actual results achieved by AngioDynamics include, without limitation, the outcome of the litigation against E2.” · word for word

Forward-looking statements highlight risks including COVID-19, competition, FDA actions, tariffs, inflation, supply chain.

“Factors that may affect actual results include COVID-19, competition, FDA actions, tariffs, inflation, supply chain”

Tariff Margin Pressure

“Tariffs, which negatively impacted gross margin by $1.4 million and $4.3 million, respectively.” · word for word

Inflation Cost Pressure

“Inflation and other operations costs, which negatively impacted gross margin by $1.3 million and $1.6 million, respectively.” · word for word

Cash Burn

“Cash used in operating activities of $14.4 million for the nine months ended February 28, 2026.”

Leadership transition risk; potential disruption during CEO search

“CEO retirement and transition period until successor found or Nov 30, 2026”

Tariff impact on gross margin

“Tariffs, which negatively impacted gross margin by $1.3 million and $3.0 million, respectively.” · word for word

Inflation and operations cost pressure

“Inflation and other operations costs, which negatively impacted gross margin by $0.5 million and $0.9 million, respectively.” · word for word